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Abstract: The chief psychoactive constituent of many bioactive phytocannabinoids
(∆9-tetrahydrocannabinol, ∆9-THC) found in hemp, cannabis or marijuana plants are scientifically
denoted by the Latin term, Cannabis sativa, acts on cell surface receptors. These receptors are
ubiquitously expressed. To date, two cannabinoid receptors have been cloned and characterized.
Cannabinoid receptor type 1 (CB1R) is found to serve as the archetype for cannabinoid action in the
brain. They have attracted wide interest as the mediator of all psychoactive properties of exogenous
and endogenous cannabinoids and they are abundantly expressed on most inhibitory and excitatory
neurons. Recent evidence established that cannabinoid receptor type 2 (CB2R) is also expressed in
the neurons at both presynaptic and postsynaptic terminals and are involved in neuropsychiatric
effects. Distinct types of cells in many regions in the brain express CB2Rs and the cellular origin of
CB2Rs that induce specific behavioral effects are emerging. To mimic the bliss effects of marijuana,
synthetic cannabinoids (SCBs) have been sprayed onto plant material, and this plant material has
been consequently packaged and sold under brand name “Spice” or “K2”. These SCBs have been
shown to maintain their affinity and functional activity for CB1R and CB2R and have been shown to
cause severe harmful effects when compared to the effects of ∆9-THC. The present review discusses
the potential brain mechanisms that are involved in the deleterious effects of SCBs.
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Introduction
Marijuana is the major often abused illegal drug (Figure 1). The degree of abuse raised from
14.5 million in 2007 to 18.1 million in 2011, with a projected about 5 million adult daily cannabis abusers.
Marijuana abuse appears to begin in the eighth grade in 1.3% of children and between 12 and 17 years
old in 7.9% of children [1]. Besides, the typical content of ∆9-tetrahydrocannabinol (∆9-THC), which is
a major psychoactive component of many bioactive cannabinoids established in the Cannabis sativa
plant [2], in marijuana has also doubled from 3.4% in 1993 to 8.8% in 2008 [3]. Moreover, an upsurge in
the concentration of ∆9-THC (13.8%) in highly potent plant varieties (sinsemilla, ‘skunk’) [3] was also
found in this period. The psychological effects that were detected after ∆9-THC use are comparable
to those observed after recreationally consumed cannabis [4]. The majority of ∆9-THC effects are
exerted via the endocannabinoid (EC) system. The EC system comprises receptors for ∆9-THC known
as cannabinoid receptors type 1 and 2 (CB1R and CB2R, respectively), endogenous receptor ligands
(‘endocannabinoids’, ECs), and EC synthesizing and degrading enzymes [5]. CB1R is ubiquitously
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expressed in brain regions, such as the hippocampus, basal ganglia, cortex, amygdala, and cerebellum,
all of which are areas connected with the behavioral effects of ∆9-THC [6]. The EC system has a
homeostatic role, but its dysfunction can promote pathological conditions [7,8].
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Figure 1. Pie illustration outlining the synthetic cannabinoid (SCB) abuse rate among high school-
going children. SCB abuse is the most widespread among young people; of the illicit drugs most used 
by high school seniors, the use of SCBs are second only to that of marijuana 
(http://www.drugabuse.gov/publications/drugfacts/spice-synthetic-marijuana). The most common 
reasons for using SCBs were affordability, inability to detect SCBs in standard drug tests, and 
perceived physical and emotional benefits. 
The CB1Rs and CB2Rs belong to the large superfamily of heptahelical G protein-coupled 
receptors (GPCR) and couple with Gi/o proteins (for more details, see reviews [5,7]). CB1R is one of 
the highly abundant GPCRs in the brain, with densities that are similar to the levels of -aminobutyric 
acid (GABA)- and glutamate-gated ion channels [9]. Functional CB2R is also present in limited 
amounts and distinct locations in the brains of several animal species, including humans [10]. The 
existence of CB2R in the brain has been acknowledged in distinct locations of the CNS in many animal 
species, including humans, in moderate levels, and is restricted to microglia and vascular elements 
[11]. However, the specific functions of this receptor in the CNS are emerging slowly. Recent strong 
evidence suggests the presence of CB2R mRNA in neuronal cells of the hippocampus [12] and 
dopamine-expressing neurons in the ventral tegmental area (VTA) [13,14]. CB2R-mediated 
regulation of cell type-specific synaptic plasticity was shown in the hippocampus [15–17]. 
Furthermore, increased CB2R levels in neurons were noticed under pathological conditions [18,19]. 
The selective agonists and antagonists of CB1R and CB2R are shown in Figures 2 and 3. 
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The CB1Rs and CB2Rs belong to the large superfamily of heptahelical G protein-coupled receptors
(GPCR) and couple with Gi/o proteins (for more details, see reviews [5,7]). CB1R is one of the highly
abundant GPCRs in the brain, with densities that are similar to the levels of γ-aminobutyric acid
(GABA)- and glutamate-gated ion channels [9]. Functional CB2R is also present in limited amounts and
distinct locations in the brains of several animal species, including humans [10]. The existence of CB2R
in the brain has been acknowledged in distinct locations of the CNS in many animal species, including
humans, in moderate levels, and is restricted to microglia and vascular elements [11]. However, the
specific functions of this receptor in the CNS are emerging slowly. Recent strong evidence suggests the
presence of CB2R mRNA in neuronal cells of the hippocampus [12] and dopamine-expressing neurons
in the ventral tegmental area (VTA) [13,14]. CB2R-mediated regulation of cell type-specific synaptic
plasticity was shown in the hippocampus [15–17]. Furthermore, increased CB2R levels in neurons
were noticed under pathological conditions [18,19]. The selective agonists and antagonists of CB1R
and CB2R are shown in Figures 2 and 3.
The stimulation of CB1R promotes its interaction with G-proteins, resulting in guanosine
diphosphate/guanosine triphosphate exchange and the subsequent dissociation of the α and βγ
subunits. These subunits regulate the activity of multiple downstream effector proteins to produce
biological functions. CB1Rs are coupled with Gi or Go proteins. However, their affinity for Gi
or Go proteins might vary, as revealed by several receptor ligands and receptor ligand-stimulated
GTPγS-binding studies [20]. CB1R activity differs from several other GPCR-G proteins, as it is
precoupled with G-proteins and it is hence constitutively functional in the absence of exogenous
agonists [21]. The CB-mediated signal transduction pathway is shown in Figure 4. Activation of CB1R
by R-(+)-methanandamide (MetAEA) and ECs in N18TG2 cells inhibited adenylate cyclase (AC) activity
(for review see [7]). In certain conditions, the enhanced AC activity was reported without Gi/o coupling
(pertussis toxin-sensitive), probably through the stimulation of Gs proteins [22]. In vitro experiments,
the expression of specific isoforms of AC (I, III, V, VI, or VIII) with the coexpression of CB1R was shown
to inhibit cyclic adenosine monophosphate (cAMP) accumulation. However, the expression of II, IV, or
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VII AC isoforms, along with the CB1R coexpression was shown to enhance cAMP accumulation [23].
Interestingly, whether the coupling of CB1R with Gs proteins has physiological function and whether
this coupling enhances after Gi or Go protein removal through colocalized noncannabinoid Gi/o
protein-coupled receptors have yet to be investigated. Further studies of the mechanism through which
CB1R stimulation primes to the buildup of GαGTPβγ heterotrimers would improve our knowledge on
the CB1R mediated signal transduction mechanisms. It is also imperative to establish whether these
heterotrimers (Gα, Gβγ, and GαGTPβγ) can cooperate with distinct downstream effector targets to
afford specificity to the signaling pathways.Brain Sci. 2019, 9, x FOR PEER REVIEW 3 of 19 
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Figure 3. The structure of selective CB1R and CB2R antagonists.
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(Figure 5). These pathways have been associated with pro-survival effects, as well as with the de novo 
synthesis of the sphingolipid messenger ceramide [24], which has been linked to the pro-apoptotic 
effects of CBs. CB2R activation by the selective agonist AM1241 contributes to the regeneration of DA 
neurons through increased activation of the PI3K/AKT signaling pathway following MPTP-induced 
neurotoxicity in mice [25]. Activation of CB2R by JWH133 induced neuroinflammation by enhancing 
the expression of MAPK phosphatase-1 (MKP-1), followed by the inhibition of MAPK signaling and 
increased blood-brain barrier permeability in a rat model of intracerebral hemorrhage (ICH) [26]. The 
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2 belongs to the seven-transmembrane domain class of GPCRs. CB2R is also coupled
to Gi/o proteins; thus, the stimulation of CB2R is associated with the inhibition of AC and the
cAMP/PKA-dependent pathway, as has been observed for CB1R. CB2R stimulation activates MAPK
cascades, specifically the ERK and p38 MAPK casca es [24]. Additionally, the activation of CB2R
has also been linked to the stimulation of additional intracellular pathways, including the PI3K/Akt
pathway [24] (Figure 5). T ese pathways have been associated with pro-survival effects, as well as
with the de novo synthesis of the sphingolipid messenger ceramide [24], which has been linked to
the pro-apoptotic effects of CBs. CB2R activation by the selective agonist AM1241 contributes to the
regeneration of DA neurons through increased activation of the PI3K/AKT signaling pathway following
MPTP-induced neurotoxicity in mice [25]. Activation of CB2R by JWH133 induced neuroinflammation
by enhancing the expression of MAPK phosphatase-1 (MKP-1), followed by the inhibitio of MAPK
signaling and increased blood-brain barrier permeability in a rat model of intracerebral hemorrhage
(ICH) [26]. The activation of CB2R is also associated with the activation of CREB, followed by increased
expression of Bcl-2, an anti-apoptotic gene leading to decreased cleaved caspase-3 levels and a e te
e rolo ical eficits i ce s arac oi e orr a e (S ) i ale rats [27]. e acti atio of
CB2R has been shown to increase G protein-coupled inward rectifying K+ (GIRK) channel activity
in pyramidal cells [28]. The activation of CB2R regulates the function of the sodium-bicarbonate
cotransporter, causing a hyperpolarization of the neuron in a self-regulatory manner, independent of
CB1R activity. These results provide additional evidence for the neuronal expression of CB2Rs and
underscore the function of CB2R in neuronal transmission [17].
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the psychoactive component in marijuana. Although these packages are labeled “not for human 
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may decrease use of SCB in the future. 
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SCBs were synthesized as research tools to investigate the function of the EC system [29]. However,
within the last decade, SCBs have been sprayed onto plant material, which has then been packaged and
sold as “Spice” or “K2”. SBCs are also sold as liquids that can be vaporized and inhaled via e-cigarettes
or other devices. These products are also identified as herbal or liquid incenses. These products mimic
the effects of marijuana [30], because SCBs act on the same CB receptors as ∆9-THC, the psychoactive
component in marijuana. Although these packages are labeled “not for human consumption”, these
products are often smoked, resulting in a marijuana-like high, as well as other physiological effects.
These products are often marketed as safe, legal alternatives to marijuana. They are dangerous and
may affect the brain much more strongly than marijuana; their particular effects can be variable and, in
some cases, fatal. Many synthetic cannabinoids (SCBs) are now classified as Schedule I drugs under
the United States (U.S.) Controlled Substances Act [31]. Because SCBs are now illegal and are classified
in the most dangerous category of scheduled drugs, manufacturers have attempted to circumvent
these laws by changing the more structurally diverse cannabimimetic compounds in their mixtures,
which might not be listed under scheduled drug regulations. In addition, “medical” marijuana is being
legalized in many states across the U.S. Therefore, individuals who previously would not have risked
the consequences of procuring an illegal drug might now consider exposing themselves to marijuana
and SCBs. In addition, the legal availability of marijuana may decrease use of SCB in the future.
SCBs were classified (Table 1) based on the chemical structures of the molecules [32].
The pharmacological effects of many SCBs vary widely and have been recently reviewed [33]. The most
frequently investigated SCBs are the aminoalkylindole WIN55,212-2, the cyclohexylphenol CP55,940,
and HU-210. Only a few studies have examined the naphthoylindoles (JWH-018 and analogs) or the
newer synthetic structural families of cannabinoids that are now dominating the “Spice” market [33].
SCBs and their metabolites have been found to possess a higher binding affinity for CB receptors than
∆9-THC, which implies greater potency, greater harmful effects, and perhaps a longer duration of
action. Although most Spice cannabinoids are widely known to be potent CB1R agonists, knowledge of
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the exact mechanisms that underlie their severe deleterious effects is largely limited. In this review, the
authors provide an integrative overview of the current research on the mechanisms that are involved
in the detrimental effects of Spice compounds.
Table 1. The Classification of Cannabinoids (CBs) [32].
Class Examples
Classical cannabinoids ∆9-THC, HU-210, AM-906, AM-411, O-1184.
Non-classical cannabinoids CP-47,497-C8, CP-55,940, CP-55,244.
Hybrid cannabinoids AM-4030.
Aminoalkylindoles JWH-018, JWH-073, JWH-398, JWH-015, JWH-122, JWH-210, JWH-081,JWH-200, WIN-55,212, JWH-250, JWH-251, Pravadoline, AM-694, RSC-4.
Eicosanoids Anandamide and methanandamide.
Others
Diarylpyrazoles (SR141716A), naphtoylpyrroles (JWH-307),
naphthylmethylindenes or derivatives of
naphthalene-1-yl-(4-pentyloxynaphthalen-1-yl) methanone (CRA-13).
Spice products comprise several SCBs, and their potency at CB1R and CB2R differ. Therefore,
their signaling mechanisms may also vary. Recently, a list of SCBs detected in Spice products,
as well as the effects of these cannabinoids, was reviewed [33]. Some known physiological effects
of SCBs are listed in Table 2. SCBs with a higher affinity for either CB1R or CB2R were shown
to elicit adverse neurobehavioral effects. The majority of SCBs found in Spice products (Table 3),
such as AM5983, AM678, AM2233, AM2389, SDB-001, AM4054, UR-144, XLR-11, JWH-081, and
JWH-073, were shown to have higher affinity for CB1R than CB2R; these SCBs are expected to
be similar to ∆9-THC in their action and suggested to be more severe than ∆9-THC, with some
of them displaying other symptoms [34]. A few SCBs found in Spice products, such as JWH-018,
AM1710, and JWH-133, shown to have a higher affinity for CB2R than for CB1R (for references,
see (https://www.drugs-forum.com/forum/showthread.php?t=117873)). Selected CB1R and CB2R
agonists appear to bind off target sites, such as sodium channels, µ and δ opioid receptors, muscarinic
acetylcholine receptors, 5-HT3 receptors, and glycine receptors (for more details see [35]). Although
details are limited, some designer drugs that are found in spice products have been shown to exert
their action through non-CB1R and CB2R targets [36–38]. However, the mechanisms by which SCBs
instigate their potentially harmful effects are not well established.
Table 2. Some known physiological effects of synthetic cannabinoids (SCBs) [33].
Raised heart rate & blood pressure
Altered state of consciousness
Mild euphoria and relaxation
Perceptual alterations (time distortion)
Intensification of sensory experiences
Pronounced cognitive effects
Impaired short-term memory
Agitation, seizures, hypertension, emesis and hypokalemia
Increase in reaction times
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Table 3. Effects of SCBs identified in Spice/K products.
SPCs Dose Animal Exposure Parameter Effects Reference
JWH-018
3 mg/kg (i.p.) Mouse Acute Cannabinoid tetrad >∆9-THC [39]
0.032 mg/kg (i.v.) Monkey Acute Drug discrimination >∆9-THC [40]






2.5 mg/kg (i.p.) Rat Acute Locomotion and catalepsy >∆9-THC [42]
5.8% (10–50 mg plant
material), inhale Mouse Acute Cannabinoid tetrad >∆
9-THC [43]
0.1–1.8 µmol/kg (i.v.) Mouse Acute Cannabinoid tetrad >∆9-THC [44]
0.03–0.3 mg/kg (i.p.) Mouse Acute Cannabinoid tetrad Induced [45]
10 mg/kg (i.p.) Mice Acute convulsion Induced [46]
2 and 3 mg/kg (vapor) Human Acute neurocognitive function andsubjective feelings Impaired [47]
1 and 100 nM HPNeuron Acute mEPSC frequency Reduced [48]
5 nM–5 µM Mouse brain slice Acute fEPSP Impaired [49]
JWH018 4-hydroxyindole
metabolite 10 mg/kg (i.p.) Mouse Acute Cannabinoid tetrad >∆
9-THC [39]
JWH-167 0.1–6.0 µmol/kg (i.v.) Mouse Acute Cannabinoid tetrad >∆9-THC [44]
JWH-203 0.13–13 µmol/kg (i.v.) Mouse Acute Cannabinoid tetrad >∆9-THC [44]
JWH-204 0.8–2 µmol/kg (i.v.) Mouse Acute Cannabinoid tetrad >∆9-THC [44]
JWH-205 13–19 µmol/kg (i.v.) Mouse Acute Cannabinoid tetrad >∆9-THC [44]
JWH-251 0.9–6 µmol/kg (i.v.) Mouse Acute Cannabinoid tetrad >∆9-THC [44]
JWH-208 2.8–38 µmol/kg (i.v.) Mouse Acute Cannabinoid tetrad >∆9-THC [44]
JWH-237 1.5–3.0 µmol/kg (i.v.) Mouse Acute Cannabinoid tetrad >∆9-THC [44]
JWH-306 1.1–2.9 µmol/kg (i.v.) Mouse Acute Cannabinoid tetrad >∆9-THC [44]
AM2389 0.1–0.3 mg/kg (i.p.) Rat Acute Hypothermia and Drugdiscrimination
>AM5983
>∆9-THC [50]
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SPCs Dose Animal Exposure Parameter Effects Reference






CP47,497 2.5 mg/kg Rat Acute Locomotion and catalepsy >JWH-018
>∆9-THC [42]





JWH-073 3.2–32 mg/kg (i.v.) Monkey Acute Drug discrimination >∆
9-THC [40]
0.1–5 mg/kg Rat Acute Locomotor activity, Anxietyand Sensorimotor gating
Reduced locomotor
activity [51]
JWH-210 0.1–5 mg/kg Rat Acute Locomotor activity, Anxietyand Sensorimotor gating
Reduced locomotor
activity [51]
AB-001 0.3–30 mg/kg (i.p.) Mouse Acute Hypothermia > JWH-018
>∆9-THC [52]
JWH-081 0.625–1.25 mg/kg (i.p.) mouse Acute LTP, Learning and memory Impaired [53]
AM-4054 0.1–1 mg/kg (s.c.) Mouse Chronic Analgesia Induced antinociception [54]
AM-4054 0.01–0.16 mg/kg (i.p.) Rat Acute Two-choice operant Impaired [55]
AM-7418 0.03-1 mg/kg (s.c.) Mouse Chronic Analgesia Induced antinociception [54]
AM-411 0.32–1 mg/kg (i.m.) Monkey Acute andChronic Drug tolerance
>WIN 55,212-2
>∆9-THC [56]





AM-2201 0.1–1 mg/kg (s.c.) Rat Acute Hypothermia and Catalepsy Induced [57]
AM-2201 20 nM–2µM Mousebrain slice Acute fEPSP Impaired [49]
UR-144 5.6 mg/kg (i.p.) Mouse Acute Cannabinoid tetrad and Drugdiscrimination >∆
9-THC [58]
XLR-11
5.6 mg/kg (i.p.) Mouse Acute Cannabinoid tetrad and Drugdiscrimination
=UR-144
>∆9-THC [59]
20 nM–5µM Mouse Acute fEPSP Impaired [49]
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Table 3. Cont.
SPCs Dose Animal Exposure Parameter Effects Reference
JWH-122 0.01–25 µM Human Endometrialstromal cell line Stress and Cell death
Enhanced stress. No
effect on cell death [60]
5F-MDMB-PINACA 1.1 mg/kg (i.p.) Rat Acute Locomotion Reduced (30 min) [61]
MDMB-CHIMICA 0.024 mg/kg (i.p.) Rat Acute Locomotion Reduced (30 min) [61]
ADB-FUBINACA 0.19 mg/kg (i.p.) Rat Acute Locomotion Reduced (60–90 min) [61]
AMB-FUBINACA 0.19 mg/kg (i.p.) Rat Acute Locomotion Reduced (60–90 min) [61]
MDMB-FUBINACA 0.04 mg/kg (i.p.) Rat Acute Locomotion Reduced (150 min) [61]
5F-AB-PINACA 10 mg/kg (i.p.) Mice Acute Convulsion Induced [46]
AB-PINACA
1–10 mg/kg (i.p.) Mice Acute Hypothermia Induced [62]








4-OH-AB-PINACA 30 and 10 mg/kg (i.p.) Mice Acute Hypothermia induced [62]
5F-AMB 300 nM Mice mPFC slices Acute Excitatory and inhibitorysynaptic transmission
Impaired sEPSP, mEPSP,
sIPSP and mIPSC [64]
MMB-FUBINACA Dose responses (i.p.) Mice Acute Drug discrimination Substituted for THC [65]
CUMYL-PICA Dose responses (i.p.) Mice Acute Drug discrimination Substituted for THC [65]
5F-CUMYL-PICA Dose responses (i.p.) Mice Acute Drug discrimination Substituted for THC [65]
NNEI Dose responses (i.p.) Mice Acute Drug discrimination Substituted for THC [65]
MN-18 Dose responses (i.p.) Mice Acute Drug discrimination Substituted for THC [65]
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DA: Dopamine; HP: Hippocampus; EPSP: Excitatory postsynaptic potentials; fEPSP: field excitatory postsynaptic potential; mPFC: medial prefrontal cortex; IPSP: inhibitory postsynaptic
potential; i.p.: Intraperitoneal; i.v.: intravenous; s.c.: Subcutaneous; i.m.: Intramuscular.
Brain Sci. 2019, 9, 14 12 of 21
JWH-081 produces acute toxicity, as demonstrated by emergency patients, perhaps as a result of
strong CB1R activation [34]. JWH-081 binds to CB1R with high affinity (1.2 nM) [74,75]. Bath application
(acute) of JWH-081 to hippocampal slices impaired long-term potentiation (LTP). This effect was absent
in CB1R KO mice slices. Thus, the adverse effects of JWH-081 on LTP are through CB1R activation.
Acute JWH-081 administration in adult mice impairs spontaneous alternation as well as spatial memory
in the Y maze and object recognition memory. The participation of pCaMKIV, pCREB, and pERK1/2,
which are critical for synaptic plasticity, learning, and memory [76] in the acute effects of JWH-081 has
also been demonstrated. JWH-081 impaired pCaMKIV and pCREB levels in the hippocampi of CB1R
WT but not KO mice. JWH-081 decreased pCaMKIV levels in a dose-dependent manner, while the
reduced pCREB was found only at a higher dose of JWH-081 (1.25 mg/kg, 30 min). JWH-081 failed to
alter pERK levels and total ERK protein levels in the hippocampi of CB1R WT or KO mice. Further,
preadministration of the CB1R antagonist SR141716A 30 min before JWH-081 treatment augmented
both loss of pCaMKIV and pCREB levels. JWH-081 exhibited greater in vitro and in vivo responses
as compared to ∆9-THC [77]. Overall, the CaMKIV-mediated phosphorylation of CREB at Ser133 is
crucial for the transcriptional activation of the CREB/CRE-mediated gene expression [78] and it has
been established to play an essential role in memory consolidation and LTP [76]. ∆9-THC significantly
reduced the pCREB levels [79] and another calmodulin kinase-related molecules, such as pCaMKII,
in a CB1R-dependent manner [80]. All ∆9-THC metabolites, except one, are inactivated through
oxidative metabolism [81], which block further CB1R stimulation. The higher affinity, potency, and
efficacy of JWH-081 [82], coupled with its likelihood to be metabolized into other metabolites [83],
demonstrates that both the acute and chronic effects of JWH-081 might be more important than those
of a similar dose of ∆9-THC. Hence, JWH-081 impairs pCaMKIV and pCREB activities through a
signaling mechanism downstream of CB1R to elicit potent deleterious neurobehavioral effects in mice
(Figure 6). The SCBs, JWH-018, AM2201, and XLR-11, all inhibit glutamate release and impair LTP in
the mouse hippocampus in a CB1R-dependent manner [49]. JWH-018 and its halogenated derivatives
(JWH-018-Cl, JWH-018-Br) dose-dependently impaired both short- and long-memory retention in
mice and diminished electrically evoked synaptic transmission, LTP, glutamate, and GABA release in
hippocampal slices [67].
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Figure 6. Schematic diagram showing the CB1R signaling mechanism of the SCBs found in Spice
products. JWH-081 and J - both act on CB1R but activate distinct CB1R sig aling events.
JWH-018, which has a higher affinity for CB2R than for CB1R, reduces pERK1/2. JWH-081, which has
a stronger affinity for CB1R than for , es not affect pERK1/2 but does impair pCaMKIV and
pCREB levels, which are linked with Arc gene expression.
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Another derivative of JWH, JWH-018, displays agonistic activity at CB1R (9 nM) and CB2R
(2.94 nM) [84] and it produces the tetrad of behaviors that are classically associated with CBs in rodent
models (analgesia, catalepsy, hypomotility, and hypothermia) [39,43], but these effects are less potent
than those that are associated with JWH-081. Chronic JWH-018 treatment also induces deficits in
spatial memory in adolescent mice [85]. JWH-018 inhibits forskolin-stimulated cAMP production [86]
and has been shown to reduce pERK levels in cultured hippocampal neurons [48]. While the effects of
JWH-081 and JWH-018 are evidently due to CB1R activation, the likely function of CB2R in the effects
of compounds that are present in “Spice” and “K2” warrant future investigation.
Another SCB, MAM-2201 (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone,
suppressed neurotransmitter release at CB1R-expressing Purkinje cell (PC) synapses in cerebellum
slices. MAM-2201 caused more significant inhibition of neurotransmitter release than ∆9-THC and
JWH-018. The reduced neurotransmitter release from CB1R-containing PC synapses could contribute
to some of the symptoms of SCB intoxication, including impairments in cerebellum-dependent motor
coordination and motor learning [87]. Several SCBs have been shown to be cytotoxic in in vitro studies.
SCBs, such as CP-47,497 and CP-47,497-C8, exhibited caspase-3- and CB1R-dependent cytotoxicity in
NG 108-15 cells, suggesting that caspase cascades may have a significant function in the apoptosis
induced by these SCBs [88]. XLR-11, at biologically appropriate doses (in the nanomolar range),
has been shown to affect mitochondrial function in human proximal tubule (HK-2) cells through a
CBR- and eCB-related mechanism. XLR-11 has been shown to induce a transient hyperpolarization
of the mitochondrial membrane and enhance ATP production, followed by Bax translocation from
the cytosol into the mitochondria. These events cause energy-dependent apoptotic cell death via
mechanisms, such as increased caspase-3 activity and chromatin condensation [89]. Furthermore,
JWH-018, JWH-073, and several major human metabolites of these compounds exhibited a high affinity
for CB2Rs in CHO-hCB2 cells, suggesting that, when CB2R is available in abundance, these SCBs and
their metabolites readily bind to CB2R with high affinity and elicit CB2R signaling [90]. The SCB
AM2201 has been shown to induce epileptic seizures by enhancing CB1R-mediated glutamatergic
transmission in the hippocampus [91].
The SCB CP-47,497-C8 was shown to induce chromosomal damage, suggesting that SCB could
cause genetic instability in SCB abusers [92]. Halogenated derivatives of JWH-018 (JWH-018 Cl and
JWH-018 Br) have been shown to impair motor activity and induce catalepsy in mice, and their
effects were more severe than those of ∆9-THC. When compared to JWH-018, JWH-018Br was less
effective at causing seizures, myoclonia, and hyperreflexia. These findings suggest that the halogenated
compounds might have been used in the Spice products to produce similar intoxicating effects as
JWH-018 while producing fewer side effects [68]. In another in vivo study, repeated administration of
JWH-018 transiently enhanced 5-HT1A receptor sensitivity to produce tolerance to its hypothermic and
cataleptic effects [36]. It has been shown that JWH-018 undergoes extensive metabolism by cytochrome
P450 (P450). The major enzyme involved in this metabolism is CYP2C9, a highly polymorphic
enzyme that is found largely in the intestines and liver. The polymorphic nature of CYP2C9 results in
variable levels of biologically active JWH-018 metabolites in some individuals, offering a mechanistic
explanation for the diverse clinical toxicity often observed following JWH-018 abuse [93]. Recently
developed SCBs, such as MMB-FUBINACA, MDMB-FUBINACA, CUMYL-PICA, 5F-CUMYL-PICA,
NNEI, and MN-18, exhibited a high affinity for human CB1R and CB2R and produced greater effects
than ∆9-THC in [35S] GTPγS binding and cAMP signaling assays. Additionally, all six synthetic
cannabinoids replaced ∆9-THC in drug discrimination, suggesting that these SCBs may possess
subjective effects that are comparable to those of cannabis. Notably, MDMB-FUBINACA, a methylated
analog of MMB-FUBINACA, exhibited a higher affinity for CB1R than the parent molecule, suggesting
that slight structural alterations could cause a larger impact on the pharmacological properties of these
drugs [65]. AM2201 and XLR-11 resulted in hypothermia in a CB1R-dependent manner in mice [94].
JWH-018 administration inhibited sensorimotor responses at lower doses, reduced spontaneous
locomotion at intermediate/high doses, and induced convulsions, myoclonia and hyperreflexia at
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high doses in male CD-1 mice. These SCB effects were CB1R-dependent and directly implicated
in SCB abuse and driving [69]. JWH-250 and JWH-073 exhibited nanomolar affinity and potency
in in vitro competition binding experiments that were performed on a mouse and human CB1R
and CB2R. In vivo administration of either JWH-250 or JWH-073 induced marked hypothermia and
increased the pain threshold to both noxious mechanical and thermal stimuli. In addition, it also
caused catalepsy, reduced motor activity, impaired sensorimotor responses (visual, acoustic and tactile),
caused seizures, myoclonia, and hyperreflexia; and, promoted aggressiveness in male CD-1 mice.
Furthermore, a microdialysis study in freely moving mice showed that systemic administration of
JWH-250 or JWH-073 stimulated dopamine release in the nucleus accumbens. The CB1R agonist AM251
fully rescued behavioral, neurological, and neurochemical effects. Furthermore, coadministration of
ineffective doses of JWH-250 and JWH-073 impaired visual sensory motor responses, augmented the
mechanical pain threshold, stimulated mesolimbic DA transmission, and affected other behavioral and
physiological parameters [71]. In other in vivo studies, JWH-018 and AKB48 facilitated spontaneous
locomotion in mice. These behavioral effects were inhibited by CB1R and dopamine (DA) D1/5 and
D2/3 receptor blockade. SPECT-CT studies with dopamine transporter (DAT) revealed that JWH-018
and AKB48 decreased [123I]-FP-CIT binding in the mouse striatum. Moreover, microdialysis studies
showed that the in vivo administration of JWH-018 or AKB48 activated DA release in the nucleus
accumbens (NAc) of freely moving mice. These results suggest that JWH-018 and AKB48 induced a
psychostimulant effect in mice, possibly by increasing NAc DA release [72]. In other in vivo studies,
5F-ADBINACA, AB-FUBINACA, and STS-135 caused hypothermia; enhanced pain threshold to
both noxious mechanical and thermal stimuli; induced catalepsy; impaired motor activity; resulted
in deficits in sensorimotor responses (visual, acoustic, and tactile); induced seizures, myoclonia,
and hyperreflexia; and, promoted aggressiveness through CB1R in mice [70]. However, the visual
sensory response that is induced by STS-135 was only partially prevented by AM 251, suggesting an
additional CB1R-independent mechanism [73]. Two recently developed SCBs (AKB48 and 5F-AKB48)
exhibited nanomolar affinity and potency at CBRs in mouse and human cell preparations in in vitro
competition binding experiments. Administration of AKB48 or 5F-AKB48 in CD-1 mice elicited
hypothermia; enhanced the pain threshold to both noxious mechanical and thermal stimuli; induced
catalepsy; impaired motor activity; resulted in defects in sensorimotor responses (visual, acoustic
and tactile); elicited seizures, myoclonia, and hyperreflexia; and, promoted aggressiveness in mice.
Moreover, a microdialysis study in freely moving mice showed that in vivo administration of AKB48
and 5F-AKB48 increased dopamine release in the nucleus accumbens. These behavioral, neurological,
and neurochemical effects were inhibited by the administration of a CB1R antagonist (AM 251).
Interestingly, a new generation of novel carboxamide synthetic cannabinoids have continued [61]
to appear in the market as marijuana alternatives to evade drug control laws and cannabinoid
blood/urine tests. For example, 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA),
MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as
FUB-AMB and MMB-FUBINACA) were found to exhibit in vivo cannabinoid-like effects. Although all
of these SCBs depressed locomotor activities, the time that is required for them to induce depressive
activity varies. For example, 5F-MDMB-PINACA and MDMB-CHIMICA induced (30 min) depression
of locomotor activity. ADB-FUBINACA and AMB-FUBINACA depressed locomotor activity for
60–90 min, whereas MDMB-FUBINACA depressed locomotor activity for 150 min. Furthermore,
AMB-FUBINACA induced tremors at the highest dose tested. Furthermore, 5F-MDMB-PINACA,
MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA completely replaced
the discriminative stimulus effects of ∆9-THC following 15-min preadministration. Together, these
findings suggest that these SCBs may have abuse potential that is comparable to that of ∆9-THC. The
AMB-FUBINACA may induce an increased risk of harmfulness in recreational users [61].
Abused SCBs have been shown to cause convulsion, but the mechanisms are not well understood.
A recent study compared the convulsant effects of ∆9-THC, JWH-018, and 5F-AB-PINACA as well
as that of a classic chemical convulsant pentylenetetrazol (PTZ) using an observational rating scale
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in mice [46]. JWH-018 and 5F-AB-PINACA elicited severe convulsions when compared to those
elicited by PTZ, and ∆9-THC failed to elicit convulsions. SR141716A, but not PTZ, blocked the effects
of JWH-018 and 5F-AB-PINACA. Nonselective inhibition of CYP450s with 1-aminobenzotriazole
(1-ABT) potentiated the hypothermic effects of JWH-018 and 5F-AB-PINACA and provided protection
against the convulsant effects of JWH-018 but not those of 5F-AB-PINACA or PTZ. These findings
suggest that SCB-elicited convulsions are facilitated by high intrinsic efficacy at CB1Rs and indicate
that drug metabolism plays an essential role in the in vivo efficacy of SCBs. Systemic administration
of JWH-073, JWH-210, and ∆9-THC failed to affect sensorimotor gating, and locomotor activity was
only partially affected. However, ∆9-THC, but not JWH-073 and JWH-210, induced an anxiolytic-like
effect [51]. In vitro experiments have suggested that AB-PINACA displays a comparable affinity for
CB1Rs but a greater efficacy for G-protein activation and a higher potency for adenylyl cyclase (AC)
inhibition than ∆9-THC. Chronic administration of AB-PINACA also causes greater desensitization of
CB1Rs (e.g., tolerance) than chronic administration of ∆9-THC. Notably, monohydroxy metabolites
of AB-PINACA retain their affinity and full agonist activity at CB1Rs. Furthermore, the systemic
administration of AB-PINACA and 4OH-AB-PINACA caused hypothermia in a CB1R-dependent
manner [62]. These data demonstrate that AB-PINACA exhibits pronounced adverse effects through
atypical pharmacodynamic properties at CB1Rs as compared to the effects of ∆9-THC by producing
metabolically stable active phase I metabolites. These findings indicate that SCBs found in Spice
products may exert their acute deleterious effect through CBR. However, a limited number of long-term
studies have suggested that SCBs may induce severe harmful effects via complex neuroadaptation
mechanisms, and future investigations on this topic are necessary.
In summary, investigation on the psychoactive components of marijuana, as well as the role of the
eCB system in humans and its relationship to various brain disorders, has received much attention
since the identification of CB receptors and their eCB ligands. Moreover, in addition to the well-known
symptoms of euphoria and pleasure, SCBs binding to CB1R can also cause anxiety, short-term memory
loss, and attention deficits and can have many other cognitive, affective, and psychomotor effects.
The extent to which brain development and functions are disturbed remains unknown in young SCB
users who have been shown to develop an increased risk of CB dependence. Although studies on the
acute effects of SCBs are underway, studies on the chronic abuse of SCB drugs are still insufficient;
thus, this area requires future attention. The immediate results of acute SCBs are probably related to
the stimulation of presynaptic CB1R-mediated signaling cascades and the inhibition of the release
of several neurotransmitters in the brain. In chronic SCB users, it can be presumed that adaptive
changes in the CB1R-mediated signaling cascades and the related neurotransmitter systems result in
severe adverse effects. It is likely that the additional compounds that were identified in the Spice/K2
preparations might also contribute, through CB1R or CB2R signaling, to the behavioral effects that are
produced by smoking “Spice/K2”. In addition, their different pharmacological characteristics might
cause the harmful effects of different preparations of “Spice/K2” to vary. Further investigation into
these additional SCBs is required. “Spice/K2” is marketed as a “natural” herbal blend but contains
at least one very potent SCB that acts through CB1R signaling, which likely accounts for the severe
deleterious effects that are elicited by smoking “Spice/K2”.
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